Facile Synthesis of Multifunctional Magnetoplasmonic Au-MnO Hybrid Nanocomposites for Cancer Theranostics

Abstract

Significant attention is paid to the design of magnetoplasmonic nanohybrids, which exploit synergistic properties for biomedical applications. Here, a facile method was employed to prepare plasmonic magnetic Au-MnO heterostructured hybrid nanoparticles for imaging-guided photothermal therapy of cancers in vitro, with the view to reducing the serious drawbacks of chemotherapy and gadolinium-based contrast agents. The biocompatibility of the prepared Au-MnO nanocomposites was further enhanced by Food and Drug Administration (FDA)-approved triblock copolymers Pluronic® F-127 and chitosan oligosaccharide (COS), with complementary support to enhance the absorption in the near-infrared (NIR) region. In addition, synthesized COS-PF127@Au-MnO nanocomposites exhibited promising contrast enhancement in T1 MR imaging with a good r1 relaxivity value (1.2 mM−1 s−1), demonstrating a capable substitute to Gd-based toxic contrast agents. In addition, prepared COS-PF127@Au-MnO hybrid nanoparticles (HNPs) produced sufficient heat (62 °C at 200 μg/mL) to ablate cancerous cells upon 808 nm laser irradiation, inducing cell toxicity, and apoptosis. The promising diagnostic and photothermal therapeutic performance demonstrated the appropriateness of the COS-PF127@Au-MnO HNPs as a potential theranostic agent.

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

“…In contrast, low-temperature PPT (43–45 ​°C) suffers due to a decrease in tumour cell killing impact [ 223 ]. Other limitations include poor targeting capability of photothermal materials that can be improved by conjugating specialized targeting ligands or proteins with nanomaterials [ 224 ]. Nonetheless, more proteins or ligands-loaded nanomaterials may have a lesser dose of therapy drugs, which shows a weakened antitumour effect resulting in recurrence and metastasis or secondary melanoma development [ 223 ].…”

“…Aside from encapsulation, safe and longer circulation in the blood vessels of breast enhance the chances of CRISPR/Cas entry in the tumour cells. A lucrative and even more effective approach is to modify the surface of nanovehicles by diverse kind of FDA approved non-toxic polymer like polyethylene glycol (PEG) [ 232 ], chitosan [ 316 ], pluronic™ F 127 (PF127) [ 224 , 323 ] and pluronic™ F 68 (PF68). Furthermore, inorganic nanovehicles aid precise targeted delivery of CRISPR/Cas cargo for in vivo therapy.…”

“…Moreover, tumour microenvironment does play a critical role in CRISPR-nano complex delivery. In this connection, inorganic nanovehicles can be exploited because they provide ample control over time-dependent cargo release upon external or internal stimuli such as light [ 136 , 283 ], photothermal [ 224 , 323 ], pH [ 311 ], ultrasound [ 218 ], thermal, hypoxia [ 296 ], ATP and redox-reagent like glutathione-triggered nanovehicles [ 296 ]. For instance, gold and silica-based nanocarriers can provide the advantage of PTT and ultrasound-depended transfection via layer-by-layer assembly method.…”

Synthesis of Multifunctional Eu(III) Complex Doped Fe3O4/Au Nanocomposite for Dual Photo-Magnetic Hyperthermia and Fluorescence Bioimaging

“…Some functional materials, such as silica, polymers, plasmon noble metals (gold, silver, etc. ), and luminescent materials, have been coated and combined with magnetic nanomaterials to improve the heating efficiency, improve biocompatibility, and expand their applicability towards theranostics [ 14 , 15 , 16 , 17 , 18 , 19 , 20 ].…”

Special Issue “Advanced Nanomaterials for Bioimaging”

“…Tian et al prepared multifunctional magnetoplasmonic Au-MnO hybrid nanocomposites for cancer theranostics. MnO exhibited promising contrast enhancement in T 1 MR imaging with good relaxivity (r 1 = 1.2 mM −1 s −1 ), and Au produced sufficient heat (62 °C at 200 µg/mL) to ablate cancerous cells upon 808 nm laser irradiation (photothermal therapy), inducing cell toxicity and apoptosis [ 22 ].…”